| Title: | Long COVID research: an update from the PHOSP-COVID Scientific Summit |
| Authors: | Brightling, CE
Evans, RA
Singapuri, A
Smith, N
Wain, LV
Brightling, CE
Evans, RA
Wain, LV
Chalmers, JD
Harris, VC
Ho, LP
Horsley, A
Houchen-Wolloff, L
Marks, M
Raman, B
Singapuri, A
Barran, P
Bingham, M
Chilvers, ER
Daynes, E
Efstathiou, CM
Elneima, O
Guillen Guio, B
Harrison, EM
Jenkins, RG
Liew, F
Lone, NI
Lord, JM
McAuley, HJC
McCann, GP
Mitchell, J
Plekhanova, T
Russell, RJ
Saunders, RM
Semple, MG
Smith, N
Trivedi, D
Turtle, L
Walker, S
Abel, K
Adamali, H
Adeloye, D
Adeyemi, O
Adrego, R
Aguilar Jimenez, LA
Ahmad, S
Ahmad Haider, N
Ahmed, R
Ahwireng, N
Ainsworth, M
Al-Sheklly, B
Alamoudi, A
Ali, M
Aljaroof, M
Allan, L
Allen, RJ
Allerton, L
Allsop, L
Allt, AM
Almeida, P
Altmann, D
Alvarez Corral, M
Amoils, S
Anderson, D
Antoniades, C
Arbane, G
Arias, A
Armour, C
Armstrong, L
Armstrong, N
Arnold, D
Arnold, H
Ashish, A
Ashworth, A
Ashworth, M
Aslani, S
Assefa-Kebede, H
Atkin, P
Atkin, C
Aul, R
Aung, H
Austin, L
Avram, C
Ayoub, A
Babores, M
Baggott, R
Bagshaw, J
Baguley, D
Bailey, L
Baillie, JK
Bain, S
Bakali, M
Bakau, M
Baldry, E
Baldwin, M
Baldwin, D
Ballard, C
Banerjee, A
Bang, D
Barker, RE |
| Issue Date: | 16-Oct-2023 |
| Publisher: | Elsevier |
| Citation: | Brightling, C.E. et al. on behalf of the PHOSP-COVID Collaborative Group (2023) 'Long COVID research: an update from the PHOSP-COVID Scientific Summit', The Lancet Respiratory Medicine, 11 (11), pp. e93 - e94. doi: 10.1016/S2213-2600(23)00341-7. |
| Abstract: | The severity of acute SARS-CoV-2 infection has decreased with the introduction of public health policies, vaccination, improved management of acute disease, and a degree of protective immunity in those who have survived past infection. However, in the wake of the pandemic, post-acute sequelae of COVID-19—referred to as long COVID—have emerged. The UK National Institute for Health and Care Excellence (NICE) describes long COVID as a condition in which signs and symptoms continue or develop after acute COVID-19 (>4 weeks), including ongoing symptomatic COVID-19 and post-COVID-19 syndrome (≥12 weeks). |
| URI: | https://bura.brunel.ac.uk/handle/2438/28325 |
| DOI: | https://doi.org/10.1016/S2213-2600(23)00341-7 |
| ISSN: | 2213-2600 |
| Other Identifiers: | ORCiD: Claire M Nolan https://orcid.org/0000-0001-9067-599X |
| Appears in Collections: | Dept of Health Sciences Research Papers
|
